Consun Pharmaceutical continues share buyback program

Consun Pharmaceutical Group Limited announced its latest share repurchase activities through a Next Day Disclosure Return filed on November 5, 2025. The company repurchased 200,000 ordinary shares on the Exchange on November 5, 2025, at prices ranging from HK$14.81 to HK$15 per share, with an aggregate price paid of HK$2,982,260. These shares are intended for cancellation, maintaining the total number of issued shares at 847,973,407.

The repurchases on November 5 are part of a broader ongoing program. As of the closing balance date, the company reported a series of share repurchases for cancellation across various dates in October and November 2025, including 320,000 shares on October 14, 2025, and 495,000 shares on November 4, 2025. The total number of shares authorized for repurchase under the mandate granted on May 22, 2025, is 85,126,334 shares, with 9,091,000 shares already repurchased on the Exchange to date, representing 10.6794% of the issued shares at the time of the mandate.

Consun Pharmaceutical confirmed these repurchases were executed in accordance with Main Board Rules. A moratorium period for new share issues or treasury share sales following these repurchases extends until December 5, 2025.